Renal Cancer

Renal Cancer

Genentech WO39210: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti – PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Exclusion Criteria:

  • Malignancies other than Renal Cell Carcinoma within 5 years prior to beginning study
  • Administration of a lice, attenuated vaccine 4 weeks before beginning study
  • Treatment with systemic immunostimulatory agents within 4-6 weeks

Study Product: Atezolizumab
Study Length: Treatment continues until disease progression


Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Stacey at (843) 449-1010 ext. 268 or email us by filling out the form below.


Please fill in the form below to email us to learn more about our trials: